May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Theanine Provides Neuroprotective Effects of Retinal Ganglion Cells in a Rat Model of Chronic Glaucoma
Author Affiliations & Notes
  • K. Hirooka
    Ophthalmology, Kagawa Medical Univ, Kita-gun, Japan
  • M. Tokuda
    Physiology, Kagawa Medical Univ, Kita-gun, Japan
  • T. Itano
    Biology, Kagawa Medical Univ, Kita-gun, Japan
  • F. Shiraga
    Biology, Kagawa Medical Univ, Kita-gun, Japan
  • Footnotes
    Commercial Relationships  K. Hirooka, None; M. Tokuda, None; T. Itano, None; F. Shiraga, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 119. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Hirooka, M. Tokuda, T. Itano, F. Shiraga; Theanine Provides Neuroprotective Effects of Retinal Ganglion Cells in a Rat Model of Chronic Glaucoma . Invest. Ophthalmol. Vis. Sci. 2003;44(13):119.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To investigate the protective effect of theanine, γ-glutamylethylamide, against neurotoxicity of retinal ganglion cells of rats with chronic moderately elevated intraocular pressure (IOP). Methods: Chronic, moderately elevated IOP was produced unilaterally in rats by cautery of three episcleral vessels. Secondary degeneration was measured with and without 1 mM theanine for 5 months. At 5 months, retinal ganglion cells were labeled with a fast blue tracer applied to both superior colliculi. Densities of surviving retinal ganglion cells were estimated by counting fast blue labeled cells in whole mounted retinas. Results: IOP was elevated in all eyes after receiving three-vessel cautery compared with control eyes. When compared with their contralateral control eyes with normal IOP, retinal ganglion cell loss in eyes with chronic, moderately elevated IOP was 30.9 ± 2.6% (n = 5) at 5 months in untreated animals and 12.1 ± 1.7% (n =5 ) at 5 months in treated animals with theanine (p < 0.05). Conclusions: Pretreatment and early posttreatment with theanine is an effective neuroprotectant in a rat model of chronic glaucoma.

Keywords: ganglion cells • neuroprotection • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×